Senner has nearly three decades of finance experience at industry-leading biotechnology and pharmaceutical companies.
He currently serves as executive vice president and chief financial officer of Exelixis, Inc., a commercially successful, oncology-focused biotech advancing medicines for difficult-to-treat cancers.
At Exelixis, Senner leads a team responsible for providing the financial infrastructure for the company's growing commercial oncology franchise, broad clinical development operations, and reinitiated drug discovery activities.
Before joining Exelixis, Senner served for five years as vice president, Corporate Finance at Gilead Sciences.
Prior to Gilead, he spent eighteen years at Wyeth, including as CFO of its US pharmaceuticals business and BioPharma Business Unit. Senner holds a B.S. in Finance from Bentley College.
Cortexyme is a privately held, clinical-stage pharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's disease and other degenerative diseases.
Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer's patients and tied to neurodegeneration and neuroinflammation in animal models.
The company's lead compound, COR388, is beginning the Phase 2/3 GAIN trial in Alzheimer's disease in 2Q19.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer